初治慢性淋巴细胞白血病患者一线与三线使用伊布替尼的成本效益
本研究建立马尔可夫模型,从美国支付方角度评估老年初治慢性淋巴细胞白血病(CLL)患者一线持续使用伊布替尼,与先采用限时苯达莫司汀和维奈克拉方案、失败后再三线使用伊布替尼两种策略的成本效益。一线伊布替尼较三线使用增加0.26个质量调整生命年(QALY)和0.40个生命年,但增量成本达612 700美元,增量成本效益比(ICER)为每QALY 2 350 041美元。作者认为,按当前定价,一线伊布替尼对未经选择的老年CLL患者不太可能具有成本效益,将伊布替尼推迟到后线使用可能是限制医疗费用而不影响临床结局的合理策略。
要点
- 一线伊布替尼较三线使用增加0.26个QALY和0.40个生命年,增量成本612 700美元。
- 一线伊布替尼的ICER为每QALY 2 350 041美元,需月费用下降72%才能在每QALY 150 000美元阈值下具成本效益。
- 作者认为按当前定价一线伊布替尼对未经选择的老年CLL患者不太可能具有成本效益。
核心结论
- 一线伊布替尼较三线使用仅增加0.26个QALY,增量成本612 700美元,ICER为每QALY 2 350 041美元。
- 作者认为按当前定价,一线伊布替尼对未经选择的老年CLL患者不太可能具有成本效益。
- 作者认为将伊布替尼推迟到后线使用可能是限制医疗费用而不影响临床结局的合理策略。
研究设计与样本
- 本研究建立马尔可夫模型,从美国支付方角度评估一线持续伊布替尼与三线使用伊布替尼的成本效益。
- 对照策略为先用限时苯达莫司汀和维奈克拉方案、失败后再三线使用伊布替尼。
- 转移概率通过参数生存模型从随机试验中估计,计算终生直接医疗费用、QALY与ICER。
主要发现
- 一线伊布替尼较三线使用增加0.26个QALY和0.40个生命年。
- 一线伊布替尼的增量成本为612 700美元,ICER为每QALY 2 350 041美元。
- 要使一线伊布替尼在每QALY 150 000美元支付意愿阈值下具成本效益,伊布替尼月费用需降低72%。
- 情景分析中,若延迟伊布替尼组在二线使用伊布替尼,一线伊布替尼较二线使用增量成本478 823美元、增量效果0.05个QALY、ICER为每QALY 9 810 360美元。
关键数值与推荐
- 评估阈值为每QALY 150 000美元的支付意愿。
- 一线伊布替尼较三线使用:增量0.26个QALY、0.40个生命年、增量成本612 700美元、ICER每QALY 2 350 041美元。
- 一线伊布替尼较二线使用(情景分析):增量成本478 823美元、增量效果0.05个QALY、ICER每QALY 9 810 360美元。
临床怎么用
- 作者认为,将伊布替尼推迟到后线使用可能是限制医疗费用而不影响临床结局的合理策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The ALLIANCE A041202 trial found that continuously administered ibrutinib in the first-line setting significantly prolonged progression-free survival compared with a fixed-duration treatment of rituximab and bendamustine in older adults with chronic lymphocytic leukemia (CLL). In this study, we created a Markov model to assess the cost-effectiveness of ibrutinib in the first-line setting, compared with a strategy of using ibrutinib in the third-line after failure of time-limited bendamustine and venetoclax-based regimens. We estimated transition probabilities from randomized trials using parametric survival modeling. Lifetime direct health care costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated from a US payer perspective. First-line ibrutinib was associated with an improvement of 0.26 QALYs and 0.40 life-years compared with using ibrutinib in the third-line setting. However, using ibrutinib in the first-line led to significantly higher health care costs (incremental cost of $612 700), resulting in an ICER of $2 350 041 per QALY. The monthly cost of ibrutinib would need to be decreased by 72% for first-line ibrutinib therapy to be cost-effective at a willingness-to-pay threshold of $150 000 per QALY. In a scenario analysis where ibrutinib was used in the second-line in the delayed ibrutinib arm, first-line ibrutinib had an incremental cost of $478 823, an incremental effectiveness of 0.05 QALYs, and an ICER of $9 810 360 per QALY when compared with second-line use. These data suggest that first-line ibrutinib for unselected older adults with CLL is unlikely to be cost-effective under current pricing. Delaying ibrutinib for most patients with CLL until later lines of therapy may be a reasonable strategy to limit health care costs without compromising clinical outcomes.
引用
- Patel KK, Isufi I, Kothari S, et al. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020. PMID: 32518952. doi:10.1182/blood.2020004922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。